Logo image
Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants
Journal article   Open access   Peer reviewed

Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants

Haresh Kirpalani, Edward F Bell, Susan R Hintz, Sylvia Tan, Barbara Schmidt, Aasma S Chaudhary, Karen J Johnson, Margaret M Crawford, Jamie E Newman, Betty R Vohr, …
The New England journal of medicine, Vol.383(27), pp.2639-2651
12/31/2020
DOI: 10.1056/NEJMoa2020248
PMCID: PMC8487591
PMID: 33382931
url
https://doi.org/10.1056/nejmoa2020248View
Published (Version of record) Open Access

Abstract

Limited data suggest that higher hemoglobin thresholds for red-cell transfusions may reduce the risk of cognitive delay among extremely-low-birth-weight infants with anemia. We performed an open, multicenter trial in which infants with a birth weight of 1000 g or less and a gestational age between 22 weeks 0 days and 28 weeks 6 days were randomly assigned within 48 hours after delivery to receive red-cell transfusions at higher or lower hemoglobin thresholds until 36 weeks of postmenstrual age or discharge, whichever occurred first. The primary outcome was a composite of death or neurodevelopmental impairment (cognitive delay, cerebral palsy, or hearing or vision loss) at 22 to 26 months of age, corrected for prematurity. A total of 1824 infants (mean birth weight, 756 g; mean gestational age, 25.9 weeks) underwent randomization. There was a between-group difference of 1.9 g per deciliter (19 g per liter) in the pretransfusion mean hemoglobin levels throughout the treatment period. Primary outcome data were available for 1692 infants (92.8%). Of 845 infants in the higher-threshold group, 423 (50.1%) died or survived with neurodevelopmental impairment, as compared with 422 of 847 infants (49.8%) in the lower-threshold group (relative risk adjusted for birth-weight stratum and center, 1.00; 95% confidence interval [CI], 0.92 to 1.10; P = 0.93). At 2 years, the higher- and lower-threshold groups had similar incidences of death (16.2% and 15.0%, respectively) and neurodevelopmental impairment (39.6% and 40.3%, respectively). At discharge from the hospital, the incidences of survival without severe complications were 28.5% and 30.9%, respectively. Serious adverse events occurred in 22.7% and 21.7%, respectively. In extremely-low-birth-weight infants, a higher hemoglobin threshold for red-cell transfusion did not improve survival without neurodevelopmental impairment at 22 to 26 months of age, corrected for prematurity. (Funded by the National Heart, Lung, and Blood Institute and others; TOP ClinicalTrials.gov number, NCT01702805.).
Algorithms Anemia - blood Anemia - mortality Anemia - therapy Cerebral Palsy - prevention & control Cognition Disorders - prevention & control Erythrocyte Transfusion - adverse effects Hearing Loss - prevention & control Hemoglobins - analysis Humans Infant, Extremely Low Birth Weight - blood Infant, Extremely Premature - blood Infant, Newborn - blood Infant, Premature - blood Infant, Premature, Diseases - blood Infant, Premature, Diseases - mortality Infant, Premature, Diseases - therapy Neurodevelopmental Disorders - prevention & control Survival Rate Vision Disorders - prevention & control

Details

Metrics

Logo image